REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$11.05
+1.75%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$11.03
From 52W high−30.85%
Volume1.52M
Market cap$1.04B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$11.03
From 52W high
−30.85%
Volume
1.52M
Market cap
$1.04B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.3x
P/E (TTM)
—
RSI (14)
32.9
MomentumView details →
1D Return
+1.75%
YTD Return
+12.55%
SummaryUpdated Jun 1, 2026
Replimune Group, Inc. (NASDAQ:REPL) is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company went public in July 2018 and specializes in developing oncolytic immuno-gene therapies, a cutting-edge approach to cancer treatment that uses genetically modified viruses to selectively target and destroy cancer cells while simultaneously activating the patient's immune system. Replimune is currently preparing for the potential commercial launch of its lead product candidate RP1, which has received breakthrough therapy designation from the FDA and has a Prescription Drug User Fee Act (PDUFA) date of July 22, 2025.
Similar companies
Latest newsMore news →
Replimune announced that TUDRIQEV is now available in the U.S. for advanced melanoma, supported by the ReplimuneConnect Plus patient access program.18d agoA class action was filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, with a lead plaintiff deadline of October 5, 2026.31d agoReplimune Group announced the appointment of Michelle DiNapoli as Chief Commercial Officer.66d ago